EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome

Christian Bjerregård Øland iD, Lise Skov Ranch, Tea Skaaby iD, Thomas Delvin, Henny Bang Jakobsen, Christian Bressen Pipper iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0304145 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Christian Bjerregård Øland und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics and Pharmacoepidemiology, LEO Pharma A/S, Ballerup, Denmark. Hauptthemen laut MEDLINE: Tacrolimus, Lymphoma, T-Cell, Cutaneous, Bias. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LEO Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Reverse causation is a challenge in many drug-cancer associations, where the cancer symptoms are potentially mistaken for drug indication symptoms. However, tools to assess the magnitude of this type of bias are currently lacking. We used a simulation-based approach to investigate the impact of reverse causation on the association between the use of topical tacrolimus and cutaneous T-cell lymphoma (CTCL) in a multinational, population-based study using topical corticosteroids (TCS) as comparator.

Methods

We used a multistate model to simulate patients’ use over time of a first- (TCS) and second-line treatment (topical tacrolimus), onset of atopic dermatitis (indication for drugs) and CTCL (the studied outcome). We simulated different scenarios to mimic real-life use of the two treatments. In all scenarios, it was assumed that there was no causal effect of the first- or second-line treatment on the occurrence of CTCL. Simulated data were analysed using Cox proportional hazards models.

Results

The simulated hazard ratios (HRs) of CTCL for patients treated with tacrolimus vs. TCS were consistently above 1 in all 9 settings in the main scenario. In our main analysis, we observed a median HR of 3.09 with 95% of the observed values between 2.11 and 4.69.

Conclusions

We found substantial reverse causation bias in the simulated CTCL risk estimates for patients treated with tacrolimus vs. TCS. Reverse causation bias may result in a false positive association between the second-line treatment and the studied outcome, and this simulation-based framework can be adapted to quantify the potential reverse causation bias.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusLymphoma, T-Cell, CutaneousBiasHumansComputer SimulationAdrenal Cortex HormonesTreatment OutcomeDermatitis, AtopicProportional Hazards ModelsSkin NeoplasmsImmunosuppressive AgentsCausalityFemale

Substanzen

TacrolimusAdrenal Cortex HormonesImmunosuppressive Agents

Autor:innen und Institutionen

  • Biostatistics and Pharmacoepidemiology, LEO Pharma A/S, Ballerup, Denmark.

ORCID-Profile: Christian Bjerregård Øland, Tea Skaaby, Christian Bressen Pipper

Förderung

  • LEO Pharma

Zitieren

APA

Øland, C. B., Ranch, L. S., Skaaby, T., Delvin, T., Jakobsen, H. B., & Pipper, C. B. (2024). Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome. PLOS ONE. https://doi.org/10.1371/journal.pone.0304145

Vancouver

Øland CB, Ranch LS, Skaaby T, Delvin T, Jakobsen HB, Pipper CB. Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome. PLOS ONE. 2024. doi:10.1371/journal.pone.0304145

BibTeX
@article{land2024,
  author = {Øland, Christian Bjerregård and Ranch, Lise Skov and Skaaby, Tea and Delvin, Thomas and Jakobsen, Henny Bang and Pipper, Christian Bressen},
  title = {Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0304145}
}
Kostenlos starten →